This site is intended for health professionals only

Sandoz completes acquisition of EBEWE Pharma


Sandoz announced today that it has completed its $1.3 billion acquisition of EBEWE Pharma’s specialty generic injectables business, paving the way for the creation of a global center of excellence in generic oncology injectables.

“We are delighted to combine EBEWE Pharma’s portfolio and pipeline of high-quality injectables with our global leadership in biopharmaceuticals, anti-infectives and other innovative technologies,” said Sandoz CEO Jeff George.

“This will greatly enhance the range of affordable generic anti-cancer medicines Sandoz offers to patients worldwide.”

In addition to globalising Austrian-based EBEWE’s operations through its integration within Sandoz, the world’s second largest generics company, the transaction offers Sandoz a complementary portfolio of differentiated generics, with more than 15 marketed products and a strong pipeline with several near-term launches.

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in clinical care at events delivered by renowned experts from CofE

Sandoz and EBEWE Pharma will now focus on implementing their joint integration plans to deliver a smooth transition for all stakeholders. A new global business unit and center of excellence is being created to improve customer service worldwide. The new unit will be based in Unterach, Austria and led by former EBEWE Pharma CEO Friedrich Hillebrand, who will join the Sandoz Executive Committee.

Key priorities for the integration include capitalising on EBEWE Pharma’s deep hospital marketing capabilities, strong customer partnerships, skills in developing differentiated generics, and expertise in injectables manufacturing. The majority of integration activities are expected to be completed shortly.

Annual sales of the global generic injectables sector were $10-12 billion in 2008, according to IMS Health, with injectable oncology medicines accounting for about 30%. Additionally, injectable oncology medicines with a total of $9 billion in annual sales are expected to lose patent protection by 2015.


Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine